Emax Model: Pharmacodynamic Dose-Response Analysis
Emax Pharmacodynamic Dose-Response Model · Also known as: Maximum Effect Model, Hyperbolic Emax Model, Sigmoidal Emax Model, Emax Farmakodynamik Modeli
The Emax model is a nonlinear pharmacodynamic model that describes the relationship between drug concentration and biological effect. Introduced by Holford and Sheiner in 1981, it characterizes dose-response curves using three fundamental parameters: the maximum achievable effect (Emax), the concentration producing half-maximal effect (EC50), and an optional baseline effect (E0). It remains the standard framework in clinical pharmacology and drug development for quantifying pharmacodynamic dose-response relationships.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use the Emax model when you have paired concentration-effect data and expect a saturable, monotonically increasing relationship with a biological ceiling. It is appropriate for in vitro receptor binding assays, ex vivo functional studies, and clinical PK/PD analyses. Key assumptions include a single predominant mechanism of action, reversible drug-receptor binding, and no time-delay between concentration and effect. It is not appropriate for U-shaped or biphasic dose-response curves, agonist-antagonist interactions without modification, or purely mechanistic pathway models. The indirect-response model or transit-compartment models are common alternatives when a temporal disconnect exists.
Strengths & limitations
- Biologically interpretable parameters (Emax, EC50) with direct pharmacological meaning, enabling cross-compound and cross-species comparisons.
- Parsimonious structure requiring only two to four parameters, reducing overfitting risk even in small clinical datasets.
- Well-established regulatory acceptance: widely used in FDA and EMA submissions for dose selection and label recommendations.
- Readily extended to sigmoidal, inhibitory (Imax), and indirect-response variants without abandoning the core framework.
- Assumes a static, instantaneous concentration-effect relationship, making it unsuitable when effect lags behind concentration due to distributional or biophase delays.
- Cannot describe non-monotonic (hormetic or inverted-U) dose-response shapes without substantial model modification.
- EC50 and Emax can be poorly identifiable when the observed concentration range does not span the inflection region of the curve, leading to wide confidence intervals.
- Baseline effect E0 and Emax are collinear in sparse data, potentially causing convergence problems or implausible negative effect estimates.
Frequently asked
What is the difference between the Emax model and the Hill equation?
The Hill equation, derived from enzyme kinetics, is mathematically identical to the sigmoidal Emax model. In pharmacology, the Hill equation with a Hill coefficient of 1 is the basic hyperbolic Emax model, while coefficients other than 1 produce the sigmoidal variant. Holford and Sheiner reinterpreted the Hill equation within a receptor-occupancy framework, giving its parameters (Emax, EC50) explicit pharmacodynamic meaning beyond curve fitting.
Can the Emax model be used to describe drug inhibition as well as stimulation?
Yes. The inhibitory Emax (Imax) model replaces stimulation with a fractional inhibition term: E = E0 × (1 − Imax × C / (IC50 + C)), where IC50 is the concentration producing 50% of maximum inhibition. This form is standard for characterizing enzyme inhibition, receptor antagonism, and suppression endpoints such as cortisol or tumor markers, and is directly analogous to the stimulatory Emax model.
How many concentration-effect data points are needed to reliably estimate Emax model parameters?
As a practical rule, at least five to six distinct concentration levels spanning from well below EC50 to well above EC50 are needed for stable estimation of E0, Emax, and EC50. When the Hill coefficient gamma is also estimated, additional data points near the inflection region improve precision. Population PK/PD approaches with many subjects but sparse individual sampling can partially compensate for limited per-subject data.
Sources
- Holford, N. H. G., & Sheiner, L. B. (1981). Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 6(6), 429–453. DOI: 10.2165/00003088-198106060-00002 ↗
How to cite this page
ScholarGate. (2026, June 2). Emax Pharmacodynamic Dose-Response Model. ScholarGate. https://scholargate.app/en/pharmacometrics/emax-model
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Dose-Response DesignExperimental design↔ compare
- Pharmacokinetic Compartment ModelPharmacometrics↔ compare